OTCMKTS:EMMA Emmaus Life Sciences (EMMA) Stock Price, News & Analysis $0.03 -0.01 (-26.95%) (As of 11/4/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest About Emmaus Life Sciences Stock (OTCMKTS:EMMA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Emmaus Life Sciences alerts:Sign Up Key Stats Today's Range$0.03▼$0.0350-Day Range$0.00▼$0.0552-Week Range$0.00▼$0.14Volume181,130 shsAverage Volume35,549 shsMarket Capitalization$1.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEmmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.Read More… The Crypto That’s Making Wall Street Sweat (Ad)The Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech giants are quietly integrating it. Venture capitalists are scrambling to invest.Click here to discover our #1 crypto for the market right now – poised for massive growth Emmaus Life Sciences Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks3rd Percentile Overall ScoreEMMA MarketRank™: Emmaus Life Sciences scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Emmaus Life Sciences.Read more about Emmaus Life Sciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Emmaus Life Sciences is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Emmaus Life Sciences is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the outstanding shares of Emmaus Life Sciences have been sold short.Short Interest Ratio / Days to CoverEmmaus Life Sciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEmmaus Life Sciences does not currently pay a dividend.Dividend GrowthEmmaus Life Sciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.00% of the outstanding shares of Emmaus Life Sciences have been sold short.Short Interest Ratio / Days to CoverEmmaus Life Sciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Emmaus Life Sciences this week, compared to 1 article on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Emmaus Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders35.00% of the stock of Emmaus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.42% of the stock of Emmaus Life Sciences is held by institutions.Read more about Emmaus Life Sciences' insider trading history. Receive EMMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Emmaus Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address EMMA Stock News HeadlinesQ&A with Madison County candidates for Probate JudgeOctober 31, 2024 | msn.comEvanescence’s Amy Lee Makes Official Presidential EndorsementOctober 31, 2024 | msn.comThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech giants are quietly integrating it. Venture capitalists are scrambling to invest.November 4, 2024 | Crypto 101 Media (Ad)Emmaus Life Sciences appoints new board memberOctober 6, 2024 | investing.comEmmaus Life Sciences (OTC:EMMA) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comWhat did Liz Allen find on Emmaus bike tour of Erie's urban gardens? It might surprise youSeptember 26, 2024 | msn.comMJH Life Sciences® shares exclusive insights from the CEOs of America’s most dynamic emerging biotech organizationsSeptember 24, 2024 | markets.businessinsider.comEmmaus Life Sciences, Inc.: Emmaus Life Sciences Reports Quarterly Financial ResultsSeptember 12, 2024 | finanznachrichten.deSee More Headlines EMMA Stock Analysis - Frequently Asked Questions How have EMMA shares performed this year? Emmaus Life Sciences' stock was trading at $0.1001 at the beginning of the year. Since then, EMMA shares have decreased by 72.9% and is now trading at $0.0271. View the best growth stocks for 2024 here. How were Emmaus Life Sciences' earnings last quarter? Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) issued its earnings results on Tuesday, September, 10th. The company reported ($0.03) earnings per share (EPS) for the quarter. The business earned $5.38 million during the quarter. How do I buy shares of Emmaus Life Sciences? Shares of EMMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Emmaus Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Emmaus Life Sciences investors own include Humanigen (HGEN), Matinas BioPharma (MTNB), Fulcrum Therapeutics (FULC), Sorrento Therapeutics (SRNE), Acasti Pharma (ACST), Actinium Pharmaceuticals (ATNM) and Entasis Therapeutics (ETTX). Company Calendar Last Earnings9/10/2024Today11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:EMMA CUSIPN/A CIK822370 Webwww.emmausmedical.com Phone(310) 214-0065Fax866-294-2611Employees60Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,730,000.00 Net Margins-26.32% Pretax MarginN/A Return on EquityN/A Return on Assets-15.32% Debt Debt-to-Equity RatioN/A Current Ratio0.14 Quick Ratio0.12 Sales & Book Value Annual Sales$29.60 million Price / Sales0.08 Cash FlowN/A Price / Cash FlowN/A Book Value($0.69) per share Price / Book-0.05Miscellaneous Outstanding Shares63,870,000Free Float41,513,000Market Cap$2.24 million OptionableNot Optionable Beta6.50 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report This page (OTCMKTS:EMMA) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emmaus Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Emmaus Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.